FY2024 Earnings Estimate for MOLN Issued By Leerink Partnrs

Molecular Partners AG (NASDAQ:MOLN) – Stock analysts at Leerink Partnrs issued their FY2024 EPS estimates for shares of Molecular Partners in a note issued to investors on Thursday, March 6th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($1.93) per share for the year. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. Leerink Partnrs also issued estimates for Molecular Partners’ Q4 2024 earnings at ($0.45) EPS and FY2025 earnings at ($1.71) EPS.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.11. Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%.

Separately, Lifesci Capital assumed coverage on shares of Molecular Partners in a report on Tuesday. They issued an “outperform” rating and a $12.00 price objective on the stock.

Molecular Partners Price Performance

Shares of MOLN stock opened at $4.62 on Monday. Molecular Partners has a 12 month low of $3.32 and a 12 month high of $12.70. The firm has a market capitalization of $186.28 million, a P/E ratio of -2.15 and a beta of 1.06. The company’s fifty day moving average price is $5.09 and its two-hundred day moving average price is $5.33.

Hedge Funds Weigh In On Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. BVF Inc. IL grew its stake in Molecular Partners AG (NASDAQ:MOLN) by 205.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,353,968 shares of the company’s stock after purchasing an additional 910,747 shares during the quarter. BVF Inc. IL owned approximately 3.35% of Molecular Partners worth $6,458,000 as of its most recent filing with the SEC. 26.55% of the stock is owned by institutional investors and hedge funds.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.